阿特佐利祖马布是第一个被批准用于膜软部肉瘤的全身治疗方法
Emilie J Bergsma1, Mariam Elgawly2, David Mancuso2
1Department of Pharmacy, University of Florida Health Shands Hospital, Gainesville, FL, USA.
The Annals of pharmacotherapy
|July 19, 2023
概括
阿特佐利祖马布 (Tecentriq) 是一种有效的免疫疗法,用于治疗成人和儿童中晚期膜软部肉瘤 (ASPS). 它显示了显著的响应率和可管理的安全性,为这种罕见的癌症提供了新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜软部肉瘤 (ASPS) 是一种罕见且具有侵略性的癌症,治疗选择有限.
- 先进的ASPS在临床实践中构成了重大挑战,需要新的治疗策略.
研究的目的:
- 审查阿特佐利祖马布 (Tecentriq) 的药理学,疗效和安全性,用于治疗不可切除或转移的ASPS.
- 评估阿特佐利祖马布作为ASPS成人和儿科患者治疗的潜力.
主要方法:
- 在主要数据库 (PubMed,MEDLINE) 和临床试验注册表中进行了全面的文献搜索.
- 包括1981年至2023年间发表的关于阿特佐利祖马布治疗ASPS的英语研究.
主要成果:
- 抗PD-L1抗体阿特佐利祖马布在49名成人和儿科患者的II期试验中显示出24%的整体响应率.
- 在6个月 (67%) 和12个月 (42%) 观察到持久的反应.
- 常见的严重不良事件包括肌肉骨疼痛,高血压和体重增加.
结论:
- 阿特佐利祖马布是FDA首个专门用于ASPS的批准治疗方法,标志着显著的进步.
- 它为ASPS患者提供了一种可行的治疗选择,具有已证明的临床疗效和可管理的安全性.
- 批准包括儿科患者,解决这一罕见疾病的关键未满足需求.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:27Tumor Immunotherapy
560
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
560
01:03Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K